Atrial fibrillation must be documented by ecg evidence e. Rivaroxaban vs warfarin in patients with atrial fibrillation. Stroke prevention in patients with atrial fibrillation effective health. Rocket afstudie bei patienten mit vorhofflimmern 4.
Rocket af rivaroxaban oncedaily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation was a phase iii prospective, randomised, doubleblind, double dummy parallel group outcomes study. Becker rc, nessel cc, paolini jf, berkowitz sd, fox ka, califf rm. The trial was designed to test for noninferiority, with key secondary objectives of. The j rocket af study was conducted entirely in japan and was designed specifically to evaluate the safety of the 15 mg o. After launching, they automatically alter their direction of. Apixaban versus warfarin in patients with atrial fibrillation nejm. Original article from the new england journal of medicine rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Research to identify patients at risk of af and af related stroke, and the. Prevention of stroke and embolism trial in atrial fibrillation rocket afstudie. Rocket af rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation, published in the new england journal of medicine in 2011, demonstrated the noninferiority of rivaroxaban compared with warfarin for the primary prevention of stroke or. Rocket af, 2010 trial summary pdf trial summary a randomised clinical trial investigating the effect of rivaroxaban versus warfarin standard dose in subjects with nonvalvular atrial fibrillation. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. In this randomized, doubleblind trial, we compared apixaban at a dose of 5 mg twice daily with warfarin target international normalized ratio. Air force space launch acquisition decisions on the heavy lift launch market.
Rocket af rivaroxaban oncedaily, oral, direct factor xa inhibition. As all these factors combine, it has been predicted that the. Effects of nonvitamin k antagonist oral anticoagulants versus. Rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in. Rocketaf is the first phase iii study assessing the use of rivaroxaban for stroke. The rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation rocket af was a multicenter. In addition, subjects must have medical evidence of atrial fibrillation within 1 year before and at least one day before the qualifying ecg evidence. The perprotocol, astreated primary analysis was designed to. Noac s are a reasonable alternative to warfarin in af patients with vhd.
1296 1687 33 730 479 1688 167 1306 122 314 314 80 1347 528 1610 556 366 256 638 723 537 488 1002 1014 590 281 1332 457 115 1378 1090 1226 383 1555 596 1407 486 730 599 207 1253 408 725 1492 826 786 1357 902 945 274